Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Launches Generic Lovenox

This article was originally published in The Pink Sheet Daily

Executive Summary

Sandoz has a monopoly on the generic enoxaparin market for now, but Teva insists its ANDA is progressing at FDA.

You may also be interested in...



Momenta, Sandoz Play Patent Defense For A Change, Seek Injunction To Prevent Teva From Launching Generic Lovenox

Firms claim Teva, which now seems close to approval, cannot manufacture enoxaparin to match Sanofi's branded Lovenox without infringing Momenta's manufacturing process.

Momenta, Sandoz Play Patent Defense For A Change, Seek Injunction To Prevent Teva From Launching Generic Lovenox

Firms claim Teva, which now seems close to approval, cannot manufacture enoxaparin to match Sanofi's branded Lovenox without infringing Momenta's manufacturing process.

Sanofi Holds Its Ground On Genzyme Bid

CEO Viehbacher defended Sanofi's $69-per-share hostile bid for Genzyme while reporting third quarter financial results -- even as the French Pharma took a hit from generic Lovenox.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS070967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel